Kinney Recruiting is home of some of the most respected legal recruiters in the world, proudly serving markets around the globe. Kinneys Asia practice includes Hong Kong, Tokyo, Beijing, Shanghai, and Singapore, among others. Our U.S. services focus on Arizona, California, Florida, Texas, and New York. Additionally, Kinney Recruiting is active in Dubai, London, Moscow, and the rest of Europe. If you are interested in legal recruiting services for your organization, or if you are a potential candidate for our services, please browse our site until you are comfortable with our philosophy and practices. Kinney Recruiting is committed to serving our clients interests in an ethical and effective manner, ultimately matching the right candidate with the perfect job. Contact us today to start your search!
For information on open opportunities, review our job posting or email HR@AspirePartnersUSA.com
For over 125 years, Farmers & Merchants State Bank has proudly operated as an independent community bank, serving the residents of Waterloo, Marshall, and the recently added Lake Mills, WI. In addition to our in-house financial services, we offer a complete range of full-service, mortgage, and internet banking options. Since our establishment in 1897, we have played a vital role in our communities and remain dedicated to their prosperity. Our team is always ready to offer guidance and support, as we consider ourselves your lifelong financial partner. Our objective is to deliver comprehensive financial services and be your trusted partner for life.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.